CaMKII REGULATION OF CARDIAC RYANODINE RECEPTORS
================================================

GENERAL CONSIDERATIONS
----------------------

Ryanodine receptors (RyRs) are the calcium release channels of sarcoplasmic reticulum (SR) that provide the majority of the calcium ions (Ca^2+^) that are needed for contraction of cardiac and skeletal muscle. In the heart, these intracellular Ca^2+^ release channels are essential for normal cell development and indispensable for life, as demonstrated by the fact that genetic ablation of *RYR2*, the gene encoding for the cardiac isoform of the RyR channel (RyR2), causes death at early embryonic stage in mice ([@B100]). In humans, single amino acid mutations in RyR2 lead to life-threatening cardiac arrhythmias, also as demonstrated by the \~160 mutations that have been linked so far to catecholaminergic polymorphic ventricular tachycardia (CPVT; [@B82]). Thus, in their intracellular environment, RyR2 channels must be finely regulated so that their output signal (Ca^2+^) may induce finely graded cell contraction without igniting cellular processes that may lead to aberrant electrical activity or pathological cellular remodeling. This review will concentrate on regulation of RyR2 by *phosphorylation*, a common post-translational process that confers dynamic functional modulation to a myriad of ion channels and transporters. In the majority of cases, phosphorylation of ion channels or transporters provides an additional layer of regulation without actually being the effector or trigger of activity, i.e., in the case of RyR channels, phosphorylation *modulates* the effect of Ca^2+^ on cardiac RyR (RyR2) or depolarization on skeletal RyR (RyR1) without having the inherent ability to open or close the channel *per se*. In a useful analogy, phosphorylation and Ca^2+^/depolarization would be similar to the "volume" and "on/off" switches, respectively, of the radio in which RyR songs are played. However, as we will see on several sections of this review, this mode of regulation is so controversial that a definitive role for RyR2 phosphorylation has not been reached yet, despite the paramount importance of this process in physiological and pathophysiological conditions. RyR2 may be phosphorylated *in vitro* and *in vivo* by several kinases, but here we will concentrate on CaMKIIδ (the most abundant CaMKII expressed in the heart and referred to here simply as "CaMKII"), and incorporate protein kinase A (PKA) whenever relevant, as these two kinases share some common transduction pathways, bear the most relevance in cardiac diseases and have been studied the most. Similarly, at least two splice variants of CaMKIIδ are expressed in cardiomyocytes, CaMKIIδ~C~ (cytosolic) and CaMKIIδ~B~ (nuclear), and we will identify their differential effect whenever appropriate.

RyR2 CHANNEL PROTEIN: COMPLEX STRUCTURE AND MULTIPLE PHOSPHORYLATION SITES
--------------------------------------------------------------------------

The RyR2 channel is a homotetrameric protein of \~2 million Da that is often complexed with several accessory proteins (see below), forming an intricate multi-protein array ([@B69]; [@B9]; [@B107]). The RyR2 monomer (almost 5,000 amino acids) is organized as a series of discrete domains, with the carboxy-terminal segment crossing the SR membrane as few as four and as many as ten times (depending on the model) and forming the Ca^2+^-permeable pore, whereas the bulk of the protein (\~90%) protrudes into the cytosol to bridge a \~15--20 nm gap between the SR and t-tubule membranes ([@B46]; [@B19]; [@B111]). The cytosolic portion of the channel contains multiple regulatory domains, most prominently Ca^2+^ activation and inactivation sites, but also binding sites for energy sensors such as nucleotides (ATP, ADP, and AMP) and inorganic phosphate, metabolites such as pyruvate, fatty acids and polyamines, and ions such as Mg^2+^, H^+^, and Cl^-^ ([@B130]; [@B35]; [@B72]). The cytoplasmic site harbors also multiple phosphorylation epitopes (see below). Therefore, the RyR2 channel may act as a molecular switchboard that integrates a multitude of cytosolic signals such as dynamic and steady Ca^2+^ fluctuations, oxidation, metabolic states, β- adrenergic stimulation (phosphorylation), etc. and transduces these cytosolic signals to the channel pore to release appropriate amounts of Ca^2+^. Furthermore, Ca^2+^ release is critically influenced by *luminal* (intra-SR) factors such as Ca^2+^ content and protein interactions, thus conferring RyR2 channels an additional role as integrative switch-valves that restrict luminal Ca^2+^ overload, e.g., during sympathetic stimulation. Most of the signal-decoding structures are integral domains of the RyR2 protein, but as if this huge structural assembly were not sufficiently complex, RyR2 channels are also capable of protein--protein interactions that allow them to bind, in some cases steadily and in other cases in a time- and Ca^2+^-dependent manner, to smaller and independently regulated accessory proteins that add another layer of versatility (and complexity) to regulation of Ca^2+^ release *in vivo*. The best known RyR2-interacting proteins are calmodulin (CaM), which tonically inhibits Ca^2+^ release ([@B6]; [@B123]) FKBP12.6, which stabilizes RyR2 closures ([@B69]; [@B56]; but see also [@B103]; [@B121]), sorcin, which inhibits Ca^2+^ release in a Ca^2+^-dependent manner ([@B34]), and the ternary complex triadin-junctin-calsequestrin, which "senses" luminal Ca^2+^ content and modulates RyR2 activity, probably by acting as direct channel ligands ([@B43]). More recently, RyR2 has been found to hold anchoring sites for PKA, protein phosphatase 1 (PP1) and 2A (PP1 and PP2A), phosphodiesterase 4D3 (PDE4D3) and CaMKII ([@B69]; [@B25]; [@B57]), underscoring the importance of RyR2 regulation by *phosphorylation*.

RyR2 AS SUBSTRATE FOR CaMKII AND PKA
------------------------------------

The multi-protein complex described above that includes kinases and phosphatases associated to the RyR2 strongly suggest that this channel is an avid target of downstream signaling effectors of the β-adrenergic system. PKA is a classical effector of the β-adrenergic pathway and, although the extent of activation of CaMKII by β-adrenergic stimulation and the precise signaling pathways involved are still incompletely understood, it is also accepted that CaMKII is involved in the inotropic and lusitropic effects of sympathetic stimulation ([@B40]). Therefore, RyR2 proteins are natural targets of PKA and CaMKII and indeed, stimulation of beating hearts with β-adrenergic agonists readily triggers phosphorylation of RyR2 ([@B99]; [@B115]; [@B8]). Which kinase phosphorylates RyR2 to a greater extent? As early as 1989 (and before the controversy surrounding the stoichiometry of CaMKII and PKA phosphorylation of RyR2 that started in 2000, see below), [@B99] reported that the extent of RyR2 phosphorylation by CaMKII was \~4 times greater than that of PKA in dog hearts. This was confirmed by [@B115] in the same animal species. Later, using phospho-specific antibodies and autoradiograms, [@B86] confirmed that CaMKII phosphorylated at least four sites per each PKA-phosphorylated site. Hence, there is significant evidence indicating that RyR2 are far better substrates for CaMKII than they are for PKA, which is not entirely surprising given that the phosphorylation consensus for CaMKII: R/K-X-X-S/T (where X is any amino acid residue) is less stringent than that for PKA: R-R-X-S/T ([@B81]; however, as we will see below, a CaMKII or PKA phosphorylation consensus does not necessarily result in CaMKII or PKA phosphorylation).

Despite the presence of multiple phosphorylation consensuses in each RyR2 subunit ([@B38]) and the fact that RyR2 channels are eager substrates for several kinases (see above), only three phospho-sites have been discovered to date. Let's discuss the most salient features of each of these sites.

Serine 2808 (S2808, mouse and human nomenclature) was first discovered by [@B115] as a CaMKII site but later [@B69], [@B114] labeled it as an exclusive PKA site, despite the fact that RyR2 channels with specific ablation of this phospho-epitope (RyR2-S2808A) were still phosphorylated by PKA ([@B8]). So, a major issue with this site is whether it's a preferred substrate for CaMKII or PKA. Since the study by [@B69] reporting that S2808 was hyperphosphorylated in heart failure patients and that its phosphorylation enhanced dramatically the activity of RyR2 channels, several groups have studied this phospho-site in detail ([@B50]; [@B86]; [@B95]; [@B25]; [@B2]; [@B118]; [@B20]; [@B54]; [@B47]; [@B66]; [@B36]), with the majority of evidence pointing to S2808 being a target for PKA, CaMKII and possibly PKG. Also, most studies find S2808 constitutively phosphorylated \[basal phosphorylation \~50--75% in several animal species and humans ([@B50]; [@B86]; [@B20]; [@B47])\], thus raising doubts that this site may be a reliable index of abnormal PKA-phosphorylation in heart failure patients. Indeed, [@B8] found that mice with genetic ablation of the S2808 phospho-epitope (RyR2-S2808A) do not alter their β-adrenergic response, have cardiomyocyte function almost unchanged, and are not significantly protected against the maladaptive cardiac remodeling induced by chronic stress. Further, although PKA phosphorylation of RyR2 modified single-channel activity, its effect was modest and occurred at activating (systolic) \[Ca^2+^\], only, not at the expected low (diastolic) \[Ca^2+^\], where it would cause significant Ca^2+^ leak ([@B13]). The lack of protection against heart failure dysfunction as well as the normal β-adrenergic response of the RyR2-S2808A mice were confirmed by [@B66], [@B126] using the same transgenic mouse line. In the scheme of [@B69], which is continuously validated and extended by additional reports by the same group (for example, [@B114]; [@B89], [@B90]), PKA phosphorylation of S2808 led to dissociation of FKBP12.6, which in turn destabilized the closed state of the channel and induced multiple subconductance states, overall increasing RyR2 Ca^2+^ fluxes, especially at diastolic \[Ca^2+^\]. However, most of the central tenets of this scheme have not been confirmed by others (reviewed by [@B38]; [@B23]; [@B31]; [@B11]; [@B106]). Specifically, [@B95] found no effect of ablating the S2808 phospho-site (RyR2-S2808A) or simulating constitutive activation (RyR2-S2808D) in the activity of the channel or its affinity for FKBP12.6. That phosphorylation of RyR2 does not appear to dissociate FKBP12.6 was also found by [@B119], [@B41]. Also, there are no reports, except by the Marks' group, indicating that RyR2 phosphorylation induces subconductance states, presumably the hallmark of FKBP12.6 dissociation. Lastly, several groups have independently reported that FKBP12.6 does not affect RyR2 activity at all ([@B103]; [@B121]) or that it has modest effects, only ([@B41]). Thus, although it is indisputable that S2808 is phosphorylated by PKA, CaMKII and possibly other kinases, the functional output of such reaction has been difficult to pin down and is the subject of intense debate. Further studies are needed and should continue to provide insights as drugs designed to prevent FKBP12.6 dissociation enter clinical trials and testing in humans.

Serine 2814 (S2814) was discovered by [@B113] as a CaMKII site and, although there is consensus that CaMKII is the preferential kinase for this site, there is less agreement that it is *the only* CaMKII site in RyR2. As mentioned above, S2808 is also a target for CaMKII, and since there are at least \~4 CaMKII sites for each PKA site, this suggests that there are still other CaMKII sites yet to be discovered. Although S2814 is only six amino acid residues downstream of S2808 and forms part of the same RyR2 "phosphorylation hot spot" ([@B106]; [@B124]) the role of S2814 has been less controversial because so far it appears to be a more specific substrate for CaMKII, despite the fact that it forms part of a non-canonical CaMKII phosphorylation consensus: ^2805^RRI[S]{.ul}QTSQV[S]{.ul}V^2815^ (S2808 and S2814 are underlined). Interestingly, another serine residue within that hot spot, S2811, is also part of a non-canonical CaMKII consensus and yet, it appears to be phosphorylated *in vitro* by PKA and CaMKII ([@B124]) and *in vivo* in mice stimulated by β-adrenergic agonists ([@B48]). Whether S2811 contributes to the effect of CaMKII phosphorylation of RyR2, or distorts the signal of phospho-specific antibodies pS2808 and pS2814 ([@B47]), making it difficult to discern the specificity of kinases for these phospho-epitopes, is still unclear. In quiescent cardiomyocytes, S2814 is barely phosphorylated (unlike S2808), and although its activity-dependent phosphorylation may be prevented by CaMKII inhibitors, the basal phosphorylation at rest is maintained by a Ca^2+^-dependent kinase other than CaMKII ([@B47]). Thus, at least two Ca^2+^-dependent kinases phosphorylate S2814, possibly leading to the same functional output (discussed below). Whether S2814 phosphorylation contributes to the inotropic effects induced by β-adrenergic stimulation has not been firmly established. However, mice with germline ablation of the S2814 phospho-epitope (RyR2-S2814A) appear more resilient than WT against a variety of cardiac insults. [@B110] found that RyR2-S2814A mice were protected from catecholaminergic- and pacing-induced tachyarrhythmias, whereas [@B5] reported that arrhythmogenic spontaneous Ca^2+^ waves that were prevalent in the *mdx* mice (Duchenne muscular dystrophy model), were suppressed by crossbreeding with the RyR2-S2814A mice. In a protocol of ischemia-reperfusion injury, the RyR2-S2814A mice exhibited significantly fewer premature beats (that could be ascribed to delayed afterdepolarizations) than WT, a protection that was not seen in mice with ablation of two phospholamban phospho-sites (PLB-DM; [@B87]). [@B85] reported by RyR2-S2814 mice fared much better than WT after TAC (transverse aortic constriction)-induced heart failure, but interestingly, were not protected against MI (myocardial infarction)-induced heart failure, proposing that CaMKII phosphorylation of RyR2 plays a role in non-ischemic forms of heart failure, only. [@B83] reported that CaMKII activation and phosphorylation of S2814 were required to induce atrial fibrillation in angiotensin-infused mice. Thus, several laboratories (albeit all of them using the same mouse line) have independently bestowed on S2814 a preponderant role in cardiac protection, wherein inhibition of S2814 phosphorylation averts the functional and structural damage to the heart induced by heart failure, atrial fibrillation, and other insults. Since it appears illogical that S2814 phosphorylation, a seemingly common reaction, was naturally designed to wreak havoc in the heart's function and structure, it is therefore important to demarcate the limits in which S2814 phosphorylation turns pathogenic. Interestingly, mice with constitutive activation of S2814 (S2814D), have structurally and functionally normal hearts without arrhythmias ([@B110]) which is surprising in the context of the presumably malicious role played by S2814 phosphorylation described above.

Finally, Serine 2030 (S2030) was found by [@B118] using classical phospho-epitope mapping. Although S2030 is squarely within a CaMKII phosphorylation consensus (^2027^R-L-L-S^2030^), oddly this site is preferentially phosphorylated by PKA, at least *in vitro*. This site, therefore, like the other sites discussed above, does not follow *in silico* predictions of kinase specificity and conforms instead to the cryptic rules of steric hindrance, topological association to specific kinases, substrate availability, etc. that operate *in vivo* and separate *predicted* from *actual* phosphorylation sites. Experiments *in vitro* revealed a major role for S2030 in the control of RyR2 activity, and in heart failure patients, it appeared as a reliable marker of RyR2 dysfunction ([@B120]), presumably even superseding S2808 ([@B69]). The RyR2 channel appears to be completely unphosphorylated at S2030 in quiescent cardiac myocytes, and phosphorylation is promoted by β-adrenergic stimulation ([@B47]), in line with *in vitro* experiments that indicate PKA phosphorylation of this site. However, the precise role of S2030 in intracellular Ca^2+^ homeostasis and cardiac performance, and its involvement in pathological states of the heart are not well understood yet. Mouse lines with genetic ablation of this site (RyR2-S2030A) have just been generated ([@B18]) and should shed light on the functional role of this novel phopho-site.

FACTORS THAT COMPLICATE INTERPRETATION OF RyR2 PHOSPHORYLATION EFFECTS
----------------------------------------------------------------------

Many lines of evidence demonstrate that RyR2 channels are phosphorylated *in vitro* and *in vivo*, but a fundamental question still pervades the field: what is the functional effect of RyR2 phosphorylation? This appears as a simple question, set for a straightforward answer, but examining the diverse and apparently opposite effects that have been published in the topic in the last \~2 decades, the only safe response seems to be that phosphorylation does *something* to RyR2 activity. All potential functional outcomes for RyR2 phosphorylation (increase, decrease, and no effect on activity) have been reported, with tantalizing hints toward, but no clear factors responsible for, the radical differences. Also, the question needs to be framed in a specific integrative context for a defined response to hold some truth. For example, whereas there is compelling evidence that PKA can alter RyR2 activity *at the single channel level* ([@B45]; [@B108]; [@B69]; [@B50]; [@B105]; [@B20]; [@B114]; [@B8]; [@B58]), multiple self-regulatory systems operating in intact cells (not to mention the whole heart) may bring down this response to undetectable levels so that the answer from the cellular viewpoint would appear to be "no effect."

Although not always sure foretellers of a defined outcome, there are some factors that modify the activity of RyR2s and are likely to complicate their response to phosphorylation. First, as stated above, RyR2 channels contain multiple phosphorylation sites that, depending on their phospho-state, may attenuate or synergize the effect of the other sites, or may require prior phosphorylation to activate the whole protein. This has become evident in experiments in which it has been possible to link variable levels of phosphorylation with defined single-channel activity ([@B20]) and also where it is clear that *phosphatases* activate RyR2 channels to higher levels than either PKA or CaMKII alone ([@B62]; [@B102]), suggesting that dephosphorylation uncovers a set of phospho-sites that modulate RyR2 activity but are not affected by either kinase. Second, RyR2 activity has long been established to be dependent on the speed of Ca^2+^ application \[as inferred by Fabiato in his classical experiments that characterized CICR ([@B33]) and demonstrated in single channel experiments ([@B44])\], and this in turn may greatly influence the overall effect of phosphorylation ([@B108]; [@B50]). For example, PKA phosphorylation of RyR2 channels increases their transient component of activity (peak activation) and accelerates their rate of adaptation to a steady level of activity. In cellular settings, this effect would translate into faster rates of Ca^2+^ release in response to a fast and transient Ca^2+^ entry (such as *I*~Ca~) and into little effects on steady RyR2 activity. In fact, experiments in which SR Ca^2+^ load and *I*~Ca~ were kept constant showed that β-adrenergic stimulation of ventricular myocytes accelerated the rate of Ca^2+^ release ([@B39]), and in permeabilized cells with constant \[Ca^2+^\], PKA had little effect on RyR2 activity ([@B60]). Thus, not all effects of RyR2 phosphorylation are detectable at constant \[Ca^2+^\], the preferred method of testing for such effects; fast and transient Ca^2+^ stimuli are required to unveil some of its most critical effects. Third, there exist self-correcting mechanisms that preclude persistent activation (or inhibition) of RyR2s in intact cells and can mitigate effects of phosphorylation in a few beats ([@B30]). These mechanisms invoke restoration of steady-state Ca^2+^ fluxes when a single component of the excitation--contraction coupling machinery is perturbed or malfunctions. Thus, in its simplest terms, if the effect of PKA phosphorylation of RyR2 channels was to cause a persistent Ca^2+^ leak (as postulated by [@B69]), then the persistent leak of Ca^2+^ would necessarily cause at least partial SR Ca^2+^ depletion, which in turn would re-tune Ca^2+^ release and stop the leak. Thus, again, RyR2 responses to phosphorylation that are discretely detected at the single channel level for a relatively long period of time, may be short-lived or undetectable in cellular settings due to self-correcting mechanisms. Lastly, other factors such as Mg^2+^ ([@B58]) and luminal \[Ca^2+^\] ([@B118]) seem to be required in just about the right quantity for phosphorylation to exert maximal effects. Overall then, the response of RyRs to phosphorylation is neither simple nor monotonous; it is complicated by factors intrinsic and extrinsic to the channel protein and depends critically on the context (molecular, cellular, whole heart) in which it is examined.

OVERVIEW OF CURRENT MODEL OF RyR2 PHOSPHORYLATION
-------------------------------------------------

Despite the recognized difficulty in linking RyR2 phosphorylation with a defined functional output, the current model of RyR2 phosphorylation is extremely simple, and needs revision. In its simplest version, PKA phosphorylation of S2808 dissociates FKBP12.6 and activates the channel by inducing long-lived subconducting states, whereas CaMKII phosphorylation of S2814 activates the channel by a different mechanism ([@B69]; [@B113]). However, this model disregards the S2030 phospho-site, a *bona fide* PKA site ([@B120]), and does not give weight to the potential contribution of *other* phospho-sites, hitherto uncovered but convincingly supported by several lines of evidence. This model also does not bode well with recent structural data, wherein S2808 and S2814, by virtue of its immediacy (only six residues apart in a \~5000 amino acid subunit), form part of a larger "phosphorylation hotspot" that encompasses S2811 and possibly T2810 (^2805^RRI[**S**]{.ul}Q**[TS]{.ul}**QV**[S]{.ul}**V^2815^; [@B124]). This phosphorylation hotspot is harbored in a flexible loop connecting two symmetrical repeats interacting with one another through β strand interactions ([@B124]). Because the flexible loop is exposed to solvent and protrudes prominently on the RyR2 surface, it is not surprising that the whole phosphorylation hotspot may be easily accessed by several kinases. Because of the tight clustering of phospho-sites in this hotspot, there emerges the interesting possibility that they all provide *functional redundancy*, i.e., phosphorylation of S2808 may lead to the same downstream effects as phosphorylation of S2811, or S2814. In this scenario, the sequential addition of phosphate groups to the hotspot would lead to a graded (instead of all-or-none) response of RyR2 to kinases, which could explain the widely variable response detected by investigators to a specific phosphorylation maneuver. Of course, this alternative model based on the phosphorylation hotspot alone does not explain the distinct effect of CaMKII and PKA on RyR2 activity (see below), and to fill this void it is necessary to invoke the participation of S2030 and likely other as-yet-unrecognized phospho-sites. Thus, in an obligatorily more complex model (**Figure [1](#F1){ref-type="fig"}**) that we call "multi-phosphosite model" ([@B106]), the differential effect of PKA and CaMKII on RyR2 activity is dictated by the integrated response of the phosphorylation hotspot *and* of additional phosphorylation sites. For example, phosphorylation of S2808 and S2030 by PKA could coordinate channel openings in response to fast calcium stimuli ([@B108]; [@B39]), and phosphorylation of S2814 and other CaMKII site(s) could open RyR2s at diastolic \[Ca^2+^\], which would translate in Ca^2+^ leak. Certainly, until we understand the molecular basis by which the phosphorylation hotspot and other phospho-sites talk to the channel's gating domains, this structurally-based model will remain speculative and incomplete. Nonetheless, it takes into consideration compelling evidence on the existence of various phosphorylation sites and departs substantially from the simplified notion that one kinase phosphorylates one site and produces one effect.

![**Multi-site model of RyR2 phosphorylation.** This model considers the three phospho-sites known to date, and gives also significant weight to other as-yet-uncovered sites. The classical sites S2808 and S2814 are part of a "phosphorylation hotspot" that is located in a protruding part of the channel, is targeted by several kinases, and may contain other phospho-epitopes not yet characterized (for example, S2811). Phosphorylation of individual residues within this hotspot may be undistinguishable by the channel's gating domain, but gradual addition of phosphate groups here may contribute to a tunable effect instead of an all-or-none response. Assuming that the phosphorylation hotspot works collectively toward a single effect, the differential regulation of PKA and CaMKII on channel gating may come about by the combined effect of each kinase on phospho-residues of the hotspot and other phosphorylation sites, such as S2030. This model also accommodates solo effects of S2030 or the phosphorylation hotspot on gating domains of the channel, as well as indirect effect on gating via interaction with classical Ca^2+^ activation sites. CaMKII and protein phosphatase 1 (PP1) are depicted close to the phosphorylation hotspot because the latter is readily phosphorylated/dephosphorylated by endogenous CaMKII and PP1. Demonstrated effect of kinases on S2808, S2814, and S2030 in intact cells or hearts is shown with a solid line, and *in vitro* effect is shown with a broken line.](fphar-05-00101-g001){#F1}

CaMKII PHOSPHORYLATION OF ISOLATED RyR2 CHANNELS
------------------------------------------------

Ryanodine receptor 2 channels have long been known to be a suitable substrate for CaMKII. In fact, in 1984, long before the controversies surrounding RyR2 phosphorylation and before the purification of RyR2, [@B88] observed that "high molecular weight proteins," later identified as RyR2 channels, were excellent substrates for CaMKII. In the experiments of [@B69], where RyR2 was initially presented as a structural scaffold for multiple accessory proteins, CaMKII was *not* identified as part of that macromolecular complex. However, [@B25] and J.H. Brown's group (reviewed in [@B40]), have provided ample evidence that CaMKII is intimately associated to RyR2 (although the actual biding site is not known), logically portending an important effect of CaMKII on modulation of RyR2 activity. At the single channel level, the preponderance of results suggests that CaMKII *activates* RyR2 channels, but again, the results are not unanimous. Let's briefly review the reports.

Although indirect evidence of RyR2 modulation by CaMKII was initially obtained by \[^3^H\]ryanodine binding assays ([@B99]), the first direct demonstration was provided by [@B115] using single channel recordings of canine RyR2 channels reconstituted in lipid bilayers. These authors observed *activation* of RyR2 channels by both, endogenous (cardiac SR-resident) and exogenous (purified from brain homogenates) CaMKII, and correlated their results with biochemical assays showing additive levels of phosphorylation by endogenous and exogenous CaMKII. This was also the report that unveiled S2808 (S2809 in dogs) as a major CaMKII site, although the proportion of the total RyR2 phosphorylation for which S2808 was solely responsible could not be determined. Thus, if the endogenous CaMKII of [@B115] is the same CaMKII intimately attached to RyR2 ([@B25]; [@B40]), it appears that this CaMKII phosphorylates a subset of RyR2 phospho-sites only, fewer than what is actually possible by exogenous CaMKII. Thus, the recurring point that emerges is that multiple CaMKII sites concur in the RyR2 protein, each potentially exerting a defined level of control in the channel and not always phosphorylated by a given experimental condition. This might have been why [@B62] detected *inhibition* of single RyR2 channel activity by exogenous CaMKII, similar to [@B99], who used exogenous CaMKII in \[^3^H\]ryanodine binding experiments. Nevertheless, multiple CaMKII sites as justification for apparent discrepancies may not be universally applied, as [@B45] found activation of RyR2 channels by CaMKII, using methods and animal species (dog) similar to [@B62]. The four studies mentioned above \[[@B115], [@B62], [@B99], [@B45]\] all used high (μM) \[Ca^2+^\] to keep the RyR2 channels open, and none of them frontally addressed the question of whether CaMKII activates RyR2 at low (diastolic) \[Ca^2+^\], a question of paramount importance given the current thinking that CaMKII increases SR Ca^2+^ leak (see below). This was technically difficult at the time because CaMKII itself was known to require Ca^2+^ as a cofactor for activation, and the Ca^2+^-free, auto-phosphorylated active form of the enzyme was not widely known. Hence, more studies are needed to clarify the Ca^2+^-dependence of CaMKII effect on isolated RyR2 channels. Lastly, in an oversimplified scheme that largely ignored the overwhelming evidence for the aforementioned multiple CaMKII sites, [@B113] found that CaMKII activated single RyR2 channels and postulated that ablation of a single phospho-site (S2815) was sufficient to inhibit CaMKII phosphorylation completely. In summary, CaMKII phosphorylation of isolated RyR2 channels is readily detected at the biochemical level, and the preponderance of results indicate that CaMKII activates RyR2 channels by targeting multiple sites; however, some studies find that CaMKII may inhibit RyR2 channel activity and the nature of this apparent discrepancy is not easily explained. Furthermore, whether CaMKII phosphorylation activates individual RyR2 channels at low (diastolic) \[Ca^2+^\] has not been firmly established yet and needs more refined studies.

EFFECT OF CaMKII ON SR Ca^2+^ RELEASE
-------------------------------------

Many studies have addressed the role of CaMKII phosphorylation in SR Ca^2+^ release and excitation--contraction coupling of intact ventricular myocytes, and most of them are detailed in excellent reviews ([@B38]; [@B23]; [@B40]; [@B24]; [@B65]; [@B12]). Here we will simplify the discussion by concentrating on the studies that have addressed the role of CaMKII phosphorylation on the most direct indicators of RyR2 function, namely, SR Ca^2+^ leak, spontaneous Ca^2+^ waves, and Ca^2+^ sparks. This circumvents the problem of interpreting CaMKII effects on RyR2 based on whole cell results or global Ca^2+^ transients, which are the product of multiple nodes of activity interacting in complex ways.

Most studies find that β-adrenergic stimulation increases SR Ca^2+^ leak, and that chronic adrenergic stimulation of ventricular myocytes such as that occurring in heart failure produces a cellular substrate favorable for generation of Ca^2+^-triggered arrhythmias. To what extent are CaMKII and RyR2 channels responsible for these effects? We examined in preceding paragraphs that, although the precise transduction pathways have not been completely elucidated yet, it is clear that CaMKII is activated upon β-adrenergic stimulation of the heart ([@B40]). In addition, a significant number of studies \[but not all ([@B122])\] find that CaMKII activation increases SR Ca^2+^ leak ([@B68]; [@B25]; [@B42]; [@B22]) and that the SR Ca^2+^ leak that is characteristically increased in heart failure ([@B52]; [@B69]; [@B2]) may be prevented by specific CaMKII inhibition ([@B117]; [@B2]; [@B21]; [@B94]; [@B85]), but not by PKA inhibition ([@B21]). Hence, making the reasonable assumption that RyR2 channels are the main pathway for SR Ca^2+^ leak, and deriving from the reports above that CaMKII activation evokes arrhythmogenic SR Ca^2+^ leak, then it is fair to conclude that CaMKII phosphorylation *activates* RyR2 at diastolic \[Ca^2+^\] to produce unchecked SR Ca^2+^ release that is capable of bringing membrane potential to threshold (delayed afterdepolarizations) and quite possibly ignite cellular pathways that lead to cardiac remodeling. From this perspective, CaMKII is presented as an arrhythmogenic, deleterious kinase, and RyR2 its main instrument of deraignment. Obviously, the seemingly belittled positive effect of CaMKII in normal cell function cannot be discounted, and a balance between physiological and pathological effects of CaMKII activation must exist *in vivo*. Thus, an emerging notion is that normally, *acute* CaMKII and PKA activation result in an increased magnitude and rate of Ca^2+^ release, respectively ([@B39]), which account in no small part for the inotropic effects of β-adrenergic stimulation. This hypothesis is supported by studies that find that CaMKII increases fractional Ca^2+^ release (reviewed in [@B3]) and that PKA increases the rate of Ca^2+^ release, only, in cells with controlled L-type Ca^2+^ channel trigger and SR Ca^2+^ content ([@B39]). The role of CaMKII in force-frequency stimulation is also well known ([@B55]). On the other hand, it appears that most of the deleterious effects of CaMKII are exerted under conditions that allow its *chronic* activation. It has become evident that CaMKII is not only a sensor of Ca^2+^ signals, but it is also exquisitely sensitive to oxidative stress ([@B63]). Oxidative stress is an important ingredient of the pathogenic recipe that deranges cardiomyocytes in atrial fibrillation, heart failure, sinus node dysfunction, and other cardiomyopathies. Thus, persistent activation of CaMKII by reactive oxygen species (ROS), is an expected (and demonstrated) side effect of many cardiac insults, and a constitutively activated CaMKII has an ample range of action (hence the name multi-functional), including several ion channels and transporters that control membrane excitability and excitation--contraction coupling ([@B14]), and others that control excitation--transcription coupling ([@B10]). Since, as we noted above, RyR2 channels are natural and avid substrates of CaMKII and are themselves affected by oxidative stress ([@B29]), the contribution of RyR2 to altered Ca^2+^ homeostasis in these cardiac pathologies is almost assured. Overall, then, CaMKII walks a fine line separating "good" from "evil," and a great part of this dichotomy is dictated by its effect on RyR2 channels and its capacity to induce (potentially excessive) SR Ca^2+^ leak. Studies aimed at demarcating the pivotal point in which CaMKII contributes to health or disease continues at great strides. Until then, inhibiting CaMKII phosphorylation of RyR2 channels as targeted approach to prevent the excessive Ca^2+^ leak and the spontaneous Ca^2+^ waves that undergird several cardiomyopathies appears enticing, but needs further studies.

CaMKII REGULATION OF INOSITOL 1,4,5-TRIPHOSPHATE RECEPTORS
==========================================================

GENERAL CONSIDERATIONS
----------------------

In the majority of mammalian cells, complex intracellular Ca^2+^ signals elicited by neurohormonal stimuli are mediated through the generation of inositol 1,4,5-triphosphate (InsP~3~) and the activation of its receptor, the InsP~3~R. InsP~3~ originates from the hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC; reviewed in [@B37]; [@B101]). Concomitant binding of InsP~3~ and Ca^2+^ is necessary for InsP~3~R activation, and this in turn leads to Ca^2+^ release within the cytoplasm. Multiple stimuli by a given agonist result in repetitive InsP~3~R-mediated Ca^2+^ releases (Ca^2+^ oscillations) that propagate as Ca^2+^ waves through the entire cell first and may ultimately stimulate neighboring cells to form inter-cellular Ca^2+^ waves. In cardiac myocytes, localization of InsP~3~Rs in the nuclear envelop underlies their role in excitation--transcription coupling, but recent evidence (mostly from atrial cells) suggest that although their abundance is low in the t-tubules and the sarcolemma, InsP~3~Rs can also rev up excitation--contraction coupling and eventually trigger cellular arrhythmias ([@B67]; [@B129]; [@B59]). Similar to RyR2 channels, InsP~3~Rs are scaffolding proteins highly regulated by ions (Ca^2+^, H^+^), nucleotides (ATP), accessory proteins (FKBP12, calmodulin), and also undergo major post-translational modifications such as phosphorylation ([@B101]). The first evidence for InsP~3~Rs phosphorylation was obtained in the late 80s by Greengard's and Sydner's groups from rat cerebella ([@B96]; [@B112]). Today, at least 15 different kinases and phosphatases, including CaMKII, are postulated to target the InsP~3~Rs and regulate their activity in an isoform- and tissue-specific manner. This second part of this review will focus on the newly discovered CaMKII site (Ser150), on the physiological consequences of CaMKII phosphorylation of InsP~3~R, and on the mechanisms by which this event may participate in cardiac Ca^2+^ signaling. Further details on the general properties of InsP~3~R and their role in cardiac myocytes may be found in excellent reviews ([@B37]; [@B53]; [@B109]; [@B101]).

InsP~3~R CHANNEL: FROM STRUCTURE TO FUNCTION
--------------------------------------------

In mammals, three different genes (*ITPR1*, *ITPR2,* and *IPTR3*) encode for \~300 kDa subunits that assemble as homo- or hetero-tetramers to form a functional InsP~3~R channel. Similar to RyR2, the low resolution of InsP~3~Rs crystals shows a mushroom-like structure with a large cytosolic *cap* constituted by the N-terminal and central regions of the protein and a short *stem*, inserted into the membrane by the C-terminal domain ([@B26]). The InsP~3~-binding domain (or "core") is located within the first amino acids of the channel, while up to eight Ca^2+^ binding sites are distributed throughout its entire sequence (including two sites within the InsP~3~-binding core; [@B73]; [@B74]; [@B80]; [@B91], [@B92]). The Ca^2+^ pore is formed by a classic P-loop between the membrane-spanning segments 5 and 6. Altogether the organization of InsP~3~Rs suggests that the opening of the channel depends on large allosteric movements that, by analogy with the RyR2s, may be finely tuned by phosphorylation ([@B111]).

Depending on the subtype, the apparent *Kd* of the receptors for InsP~3~ varies from 10 to 80 nM (with InsP~3~R-2\>\>InsP~3~R-1\>InsP~3~R-3; [@B78]). Remarkably, the binding of InsP~3~ to the receptor channel is stoichiometric and regulates the properties of the InsP~3~R-mediated Ca^2+^ release. At low intracellular concentrations, InsP~3~-binding induces the opening of single InsP~3~R channel promoting a unitary Ca^2+^ release (dubbed "Ca^2+^ blip"). Increasing InsP~3~ concentrations facilitate the opening of clusters of InsP~3~Rs, allowing CICR within a cluster. At high concentration, InsP~3~ promotes CICR between the clusters and intracellular Ca^2+^ waves ([@B15]). A noteworthy property of the InsP~3~Rs is their high affinity for Ca^2+^, causing maximal activity at diastolic \[Ca^2+^\]~i~ (100 nM) while in similar conditions RyR2 are closed ([@B84]). Therefore in myocytes stimulated by Gq--protein coupled receptor (GqPCR) agonists, InsP~3~Rs-mediated Ca^2+^ release may occur during diastole and "prime" the RyR2 to open, thus potentially increasing RyR2-mediated SR Ca^2+^ leak and triggering of arrhythmias ([@B67]; [@B129]; [@B59]).

EFFECT OF CaMKII PHOSPHORYLATION ON InsP~3~R ACTIVITY
-----------------------------------------------------

Since the first reports of InsP~3~R phosphorylation more than two decades ago ([@B96]; [@B112]), the growing number of kinases that target InsP~3~Rs and either decrease or increase their activity have uncovered the complexity of InsP~3~Rs regulation. Among those enzymes, recent observations demonstrate that CaMKII plays a critical role for InsP~3~R function.

The consequences of CaMKII phosphorylation of InsP~3~R were first ascertained in permeabilized embryonic mouse fibroblasts ([@B125]). In these cells, CaMKII phosphorylation permits the activation of the InsP~3~R channel upon addition of InsP~3~ or an agonist cocktail (bradykinin + GTPγS). This activation takes place at intracellular \[Ca^2+^\] ranging from 30 to 100 nM. At higher \[Ca^2+^\]~i~, calcineurin activity prevails and dephosphorylation of the channel occurs. In agreement with these results, [@B17] observed that CaMKII enhanced the InsP~3~-sensitive Ca^2+^ flux in rat cerebellum microsomes. However, these outcomes were challenged by observations made in intact HeLa cells stimulated by histamine ([@B127]). In this model, it is the Ca^2+^ released by the InsP~3~R that activates CaMKII, which phosphorylates back InsP~3~R to terminate the release. In a second step, the activation of a phosphatase (likely PP1/PP2A) dephosphorylates InsP~3~Rs to restore its activity. This model is particularly elegant since the authors also demonstrated that activated CaMKII facilitates the ER Ca^2+^ refilling by increasing SERCA activity (likely through PLN phosphorylation). As a consequence, the alternation between phosphorylated and dephosphorylated states of InsP~3~Rs seemed to be the basic mechanism for histamine-induced intracellular Ca^2+^ oscillations (**Figure [2](#F2){ref-type="fig"}**, *left panel*). Later, similar inhibitory effects of InsP~3~Rs phosphorylation by CaMKII were reported in channels reconstituted in lipid bilayers ([@B7]) as well as in *Xenopus* oocytes ([@B70]) and bovine endothelial cells ([@B4]). Today, the origin of these conflicting observations remains unclear but a fair approximation is that it is linked to the high variability of the InsP~3~Rs sequence induced by alternative splicing, or to tissue-specific expression of accessory proteins ([@B37]).

![**CaMKII phosphorylation of Ser150 as a modulator of InsP~3~R-mediated Ca^2+^ release.** The activation of GqPCRs leads to the production of InsP~3~ by PLC and initiates InsP~3~R-mediated Ca^2+^ release. The released Ca^2+^ activates CaMKII, which in turn phosphorylates InsP~3~R-S150 to inhibit channel function. Depending on the intracellular location, CaMKII phosphorylation of InsP~3~Rs could be implicated in multiple responses. In the endoplasmic reticulum of most of the mammalian cells (*left panel*), CaMKII phosphorylation of S150 alternates with protein phosphatases dephosphorylation to trigger intracellular Ca^2+^ oscillations and mediate complex Ca^2+^ signals. In the SR of cardiac myocytes (*middle panel*), InsP~3~Rs are able to activate RyR2s by CICR even though they seem to be excluded from the dyadic cleft. This increases Ca^2+^ transients and might trigger delayed afterdepolarizations (via NCX activation). CaMKII phosphorylation of InsP~3~R-S150, which has not been determined yet, could then prevent the uncontrolled activation of RyR2s and decrease the incidence of arrhythmias. In the nucleus (*right panel*), InsP~3~R Ca^2+^ release activates CaMKII, which phosphorylates HDAC proteins to promote transcription. S150- phosphorylation by CaMKII could limit InsP~3~Rs activation in time and space. However, if associated with calcineurin-dephosphorylation of S150, CaMKII could favor InsP~3~R-dependent Ca^2+^ oscillations as secondary mechanism to activate gene expression. ATPase, sarco/endoplasmic reticulum Ca^2+^ ATPase; NFAT/CN, NFAT-calcineurin complex; DAD, delayed after depolarization; DAG, diacylglycerol; GqPCR, Gq--protein coupled receptor; HDAC, histone deacetylase; LTCC, L-type Ca^2+^ channel; MEF2, myocyte enhancer factor-2; NCX, Na^+^/Ca^2+^ exchanger; PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-bisphosphate; PP, protein phosphatase (1, 2A, and/or 2B).](fphar-05-00101-g002){#F2}

Recently, [@B73], [@B71] identified Ser150 (S150) as a distinct CaMKII phosphorylation site on InsP~3~R-2s. They demonstrated in lipid bilayers that the replacement of S150 by the non-phosphorylatable residue alanine (InsP~3~R-2^S150A^) abrogates the inhibitory effects of CaMKII phosphorylation. Conversely, the phospho-mimetic mutant InsP~3~R-2^S150E^ reproduced the blunted channel activity of phosphorylated WT receptors. Noticeably, S150 belongs to a suppressor domain located prior to the InsP~3~-binding core. The ablation of that domain increases InsP~3~R affinity for InsP~3~ but additionally blocks Ca^2+^ release by the channel ([@B104]). The proposed mechanism is that the suppressor domain participates in the transduction of the allosteric movements that are necessary for channel opening ([@B104]). Therefore, it is possible that phosphorylation of S150 by CaMKII also blocks the transmission of the activation signal to the pore domain rather than decreasing the affinity of the InsP~3~Rs for the InsP~3~. This hypothesis is reinforced by the fact that high \[InsP~3~\]~i~ is not able to reverse the inhibition of InsP~3~Rs activity after CaMKII phosphorylation ([@B127]).

InsP~3~R IN THE HEART: CONSEQUENCES OF CaMKII PHOSPHORYLATION
-------------------------------------------------------------

The mammalian heart expresses all three InsP~3~R isoforms. InsP~3~R-1 is abundant in endothelial cells and Purkinje fibers. InsP~3~R-2 is the main isoform of cardiac myocytes and pacemaker cells. Finally, InsP~3~R-3s are present in all cell types but at a lower level (5--15% total InsP~3~R expression; [@B79]; [@B61]; [@B51]). Although the roles of InsP~3~Rs in the cardiac function have been overlooked, recent evidence assigns to InsP~3~R-2s an important role in pathologic hypertrophy and Ca^2+^-triggered arrhythmias.

### InsP~3~R-2, CaMKII, and excitation--transcription coupling

In both atrial and ventricular myocytes, InsP~3~R-2s are mainly present in the nuclear envelope where their implication in pathological excitation--transcription coupling has been recently uncovered (reviewed in [@B53]). During cardiac hypertrophy induced by pressure overload or chronic activation of the GqPCRs, the InsP~3~R-2s activation leads to a subsequent release of Ca^2+^ in the nucleoplasm, which activates the nuclear isoform of CaMKIIδ (CaMKIIδ~B~). CaMKIIδ~B~ phosphorylates the histone deacetylases (HDACs) to induce their nuclear export and relieve their inhibition on the transcription factor MEF-2 (myocyte enhancer factor-2; [@B128]; [@B116]; [@B1]). In this context the inhibition of the InsP~3~Rs by a CaMKIIδ~B~ feedback phosphorylation would limit in time and space the InsP~3~R-mediated Ca^2+^ release and consequently be anti-hypertrophic. Conversely, a possible pro-hypertrophic role for CaMKIIδ~B~ phosphorylation of InsP~3~R is borne out from recent observations. First, InsP~3~R-mediated Ca^2+^ release is able to activate two targets of calmodulin: CaMKIIδ~B~ and calcineurin, a perinuclear phosphatase that translocates to the nucleus complexed with the transcription factor NFAT (reviewed in [@B76]; [@B16]). The inhibition of either CaMKII or calcineurin prevents the InsP~3~R-mediated cardiac hypertrophy ([@B77]; [@B98]; [@B128]). Second, in addition to their classical localization in the sarcolemma, GqPCRs have been recently identified in the nuclear envelope as well as in t-tubules that spread near the nucleus of cardiomyocyte ([@B97]; [@B49]). This allows for a rapid and local production of InsP~3~ that diffuses and signals into the nucleus independently from the cytosolic InsP~3~ concentration ([@B49]). Finally, [@B64] showed that neonatal rat cardiac myocytes stimulated by a GqPCR agonist exhibit repetitive InsP~3~R-mediated Ca^2+^ waves (or Ca^2+^ oscillations) that take place in the nucleus autonomously from the cytosolic \[Ca^2+^\]. Interestingly, frequency-dependent Ca^2+^ oscillations have been shown to increase gene expression via the activation of the calcineurin/NF-AT pathway ([@B27]). Altogether, these observations suggest that hypertrophic signals may be generated by intra-nuclear Ca^2+^ oscillations independently (frequency, amplitude, and duration) from the excitation--contraction coupling. InsP~3~-dependent oscillations would be created through InsP~3~Rs activation--inhibition cycles mediated by calcineurin dephosphorylation and CaMKIIδ~B~ phosphorylation of S150, respectively (**Figure [2](#F2){ref-type="fig"}**, *right panel*).

### InsP~3~R-2, CaMKII, and excitation--contraction coupling

In cardiac myocytes, the expression of InsP~3~R-2s is remarkably low compared to RyR2s (for an InsP~3~R-2:RyR2 ratio of 1:50 to 1:100 in ventricular myocytes). In addition, most of the immunofluorescence studies that have observed partial localization of InsP~3~R-2s in the sub-sarcolemmal space of atrial myocytes, failed to detect InsP~3~R-2s in the surface sarcolemma or t-tubules of ventricular myocytes ([@B7]; [@B32]; except [@B75]). Activation of InsP~3~R-2s by a GqPCR agonist produces, in the myocyte, a small and slow cytosolic Ca^2+^ spark-like release dubbed "Ca^2+^ puffs" ([@B53]). Ca^2+^ puffs can activate the neighboring RyR2s to increase the Ca^2+^ spark frequency and the Ca^2+^ transient amplitude. In pathological conditions, InsP~3~R-2 mediated Ca^2+^ release can ultimately cause, in atrial cells, Ca^2+^ alternans and increased susceptibility to arrhythmias ([@B67]; [@B129]; [@B59]). Moreover, although their expression is not detected in t-tubules, some reports support a similar role for InsP~3~R-mediated release in ventricular myocyte ([@B28]; [@B93] but not [@B67]; [@B129]; [@B59]). All together, these data suggest that InsP~3~R-2s are not directly involved in excitation--contraction coupling but participate as modulators that "prime" the RyR2s to increase their sensitivity to diastolic \[Ca^2+^\] and LTCC current. In that context, the inhibition of InsP~3~R-dependent Ca^2+^ release following CaMKIIδ~C~ phosphorylation of InsP~3~R-Ser150 would block RyR2 potentiation and exert an anti-arrhythmic effect. However, in an extensive phospho-proteome analysis that identified the vast majority of proteins phosphorylated during β-adrenergic stimulation in mice, [@B48] failed to detect phosphorylation of the cardiac InsP~3~R-2s, including S150, while InsP~3~R-1 and -3 were targeted by PKA at Ser1588 and Ser934, respectively. This suggests that the InsP~3~R-2 channels expressed in the SR are not located in the vicinity of the CaMKIIδ~C~/PKA microdomains, and therefore they may be excluded from the dyad containing the RyR2s (**Figure [2](#F2){ref-type="fig"}**, *central panel*). In agreement with that result, [@B93] described in mouse ventricular myocytes that the InsP~3~R-2 effects are mediated through the activation of the NCX and the increase of the action potential duration rather than a direct effect on RyR2s. Overall, these observations suggest an absence of a direct cross-talk between RyR2s and InsP~3~Rs and advocate the hypothesis that InsP~3~Rs mediate their effects on RyR2s by limited Ca^2+^ diffusion from the InsP~3~R release sites to the RyR2 sites.

Interestingly, [@B48] also identified two cardiac-specific epitopes on InsP~3~R-3 (Ser930 and Ser2189) for which the targeting kinase(s) remain(s) undetermined. Noticeably, S2189 of InsP~3~R-3 contains the CaMKII consensus sequence ([@B81]) and is absent from InsP~3~R-1 or -2. More studies will be necessary to determine whether this InsP~3~R-3 phosphorylation occurs in cardiac myocytes and the mechanisms by which it affects cardiac function.

CONCLUDING REMARKS
==================

CaMKII is a pleiotropic kinase that targets several ion channels and transporters in the heart, and RyR2 and InsP~3~R channels are among its principal substrates. Interestingly, despite the relatively strong structural similarity between these two intracellular Ca^2+^ release channels, the majority (but not all) of the studies indicate that CaMKII phosphorylation of RyR2s and InsP~3~Rs leads to antithetical outcomes. On one hand, CaMKII phosphorylation is presumed to *increase* RyR2 activity and promote SR Ca^2+^ leak that, when excessive, may trigger cardiac arrhythmias. On the other hand, CaMKII phosphorylation of nuclear InsP~3~Rs is presumed to *inhibit* InsP~3~Rs-mediated Ca^2+^ release and to prevent intra-nuclear Ca^2+^ oscillations (although cytosolic InsP~3~R-mediated Ca^2+^ release seems to promote arrhythmias, too). The magnitude of the effect of phosphorylation on these channels is also purportedly different since CaMKII *modulates* RyR2 channel activity, only, while it appears to play an on/off function on InsP~3~Rs. The bases of both of these differences are not immediately apparent and in fact, there is no universal agreement that such differences exist. As can be derived from the preceding paragraphs, a unified scheme on the effect of phosphorylation on both, RyR2 and InsP~3~Rs is yet to be forged. Nonetheless, independent of its precise mechanism of action on these channels, an emerging notion is that *excessive* CaMKII activity is detrimental for cardiac performance, and the potential salutary effect of blocking its chronic effects appears worth pursuing since its action on RyR2s and InsP~3~Rs might prevent both Ca^2+^-mediated arrhythmias and Ca^2+^-dependent activation of hypertrophic gene programs.
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